How fast will I lose weight on GLP-1s and is it sustainable?

Short answer

• Many people start losing weight within weeks. Typical, evidence-based amounts are roughly:
  • 3 months: often 5% or so of starting body weight (wide variability).
  • 6–12 months: average 10–15% with semaglutide (Wegovy/ozempic doses used for weight loss); somewhat larger average losses (often ~15–20% or more) with tirzepatide (Zepbound for weight, Mounjaro for diabetes) in clinical trials.
  • Some people lose less; a minority lose >20%. Response depends on drug, dose, starting BMI, behavior changes, and adherence.

Is it sustainable?

• Partly yes — as long as you stay on the medication plus maintain lifestyle changes. Clinical trials and withdrawal studies show that much or all of the lost weight is often regained if the drug is stopped and lifestyle behaviors aren’t maintained. In practice many people need long‑term (sometimes indefinite) therapy, ongoing diet/behavior support, and monitoring to keep weight off.

Important factors that change speed and sustainability

• Which drug and dose: tirzepatide in trials generally produced larger average losses than semaglutide at the doses tested. Brand examples: Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide for weight) are FDA‑approved for obesity; Ozempic (semaglutide) and Mounjaro (tirzepatide) are diabetes meds sometimes used off‑label for weight.
• Starting weight/BMI: higher starting weight usually means larger absolute kg loss.
• Diet, exercise, and behavior therapy: combining medication with lifestyle changes gives better and more durable outcomes.
• Tolerability and adherence: GI side effects are common early (nausea, constipation, diarrhea) and can limit dosing; sticking with the planned dose escalation helps reach effective levels.
• Medical conditions and other meds: insulin or sulfonylureas increase hypoglycemia risk and need dose adjustment; gallstones and pancreatitis risk rises with rapid weight loss.

Safety and monitoring

• Common side effects: nausea, vomiting, diarrhea, constipation, abdominal pain; usually improve over weeks.
• Less common but important: gallbladder disease, pancreatitis, and interactions with diabetes drugs — discuss with your prescriber. Not for use in pregnancy.
• Your clinician should check baseline labs, review meds, and monitor during treatment.

Practical next steps

• Talk with a clinician who can prescribe and monitor therapy. If interested in prescription options to discuss: Wegovy (semaglutide) and Zepbound (tirzepatide) — both showed strong results in trials; Ozempic and Mounjaro are diabetes formulations sometimes used off‑label.
• Ask about expected timeline for you, side‑effect management, coverage/cost, and a plan for long‑term maintenance (behavioral support, exercise plan, follow‑up).

If you’d like, tell me your starting weight/BMI, current meds, and whether you have diabetes or other medical issues, and I can give a more personalized expectation and a list of questions to bring to your prescriber.